Date: 2012-07-03
Type of information: Capital increase
Company: Genfit (France)
Investors: undisclosed historical shareholder
Amount: € 500 000
Funding type: capital increase
Planned used:
Others: Genfit, a french biopharmaceutical company focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, has announced a capital increase of a gross amount of €500,000.40 (issue premium included), reserved to one of its historical shareholders.
The operation was performed following the decisions of the Management Board of June 28th and 29th 2012, taking into account the volume-weighted average share price during the five consecutive trading days preceding the operation, and according to the delegations granted to the Management Board by the Nineteenth and Twentieth Resolutions of the Extraordinary General Meeting of Shareholders held on June 26, 2012. The operation will result in the issue of 416,667 new shares immediately assimilated with existing shares. The number of shares that make up the capital will thus increase to 15,085,665.
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Liver diseases
